Equity: U.S. Biotech
With 7 ETFs and over $15.58B in combined AUM, the Equity: U.S. Biotech segment provides exposure to the U.S. space with a focus on Health Care securities.
Year-to-date, the best-performing ETF in the segment is the Loncar Cancer Immunotherapy ETF (CNCR), with a total return of 12.76%. Meanwhile, the most popular ETF is the iShares NASDAQ Biotechnology ETF (IBB) with $8.92BB in assets under management.
Investors should take a look at the (). This fund has been chosen as an Analyst Pick by FactSet, thus is the best ETF for the average investor. has an expense ratio of -- and tracks the .
ETF.com Efficiency Insight
The average efficiency score in the Equity: U.S. Biotech segment is 93 out of 100, with the SPDR S&P BIOTECH ETF(XBI) obtaining the highest rating of 98 out of 100.
Costs dominate the discussion around efficiency. ETFs in the segment have an average expense ratio of 0.62% per year, with the SPDR S&P BIOTECH ETF (XBI) having the lowest expense ratio, charging investors 0.35% yearly.
Investors should look for funds with tight tracking, such as the SPDR S&P BIOTECH ETF (XBI), with a 12-month median tracking difference of -0.10%.
ETF.com Tradability Insight
The average tradability score in the Equity: U.S. Biotech segment is 90 out of 100, with the iShares NASDAQ Biotechnology ETF(IBB) obtaining the highest rating of 98 out of 100.
The SPDR S&P BIOTECH ETF (XBI) is the undisputed segment leader when it comes to liquidity. The fund trades 404.48M in daily average volume. Investors should also find ample liquidity in the iShares NASDAQ Biotechnology ETF (IBB), with $282.31M in daily dollar volume.
Use limit orders to trade funds such as the Virtus LifeSci Biotech Clinical Trials ETF(BBC), due to their double-digit market spreads.
ETF.com Fit Insight
The Thomson Reuters US Biotechnology & Medical Research has been selected as the index that most accurately represents the market in question. The benchmark has been selected by the ETF Analytics team at FactSet, according to a series of guidelines to ensure this index accurately captures its market.
Investors trying to match a broad market exposure should pay attention to IBB. This fund obtains a high Fit score and investors should capture market-like returns.
Other funds diverge from the market, by nature of their investment mandates; for example, XBI follows a Equal strategy and obtains a low Fit score compared with our neutral benchmark.